Shares of BioCryst Pharmaceuticals Inc (NASDAQ: BCRX), engaged in designing, optimizing and developing drugs that block enzymes involved in the pathogenesis of diseases, reported over 12.2% gain during each of the past two consecutive trading sessions with significant number of shares exchanging hands. BCRX was among the top performers of U.S. healthcare sector, having gained 12.4% and closed at $12.80 Friday, while recording significant trading volumes of 7.5 million shares. The rise in stock’s price came in the wake of Centers for Disease Control and Prevention (CDC) confirming the first case of Ebola virus in the U.S. and BCRX will be conducting trials on primates for its broad-spectrum Ebola drug candidate, BCX4430, in collaboration with the National Institute of Allergy and Infectious Diseases. During the past 5-trading sessions, BCRX gained 20.1% with daily average trading volumes of 3.0 million shares, while the stock accumulated over 3.8% during the past one month with daily average trading volumes of 1.2 million shares. The stock is 68.4% year-to-date.
Company Description:
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) designs, optimizes and develops small-molecule novel pharmaceuticals that block key enzymes involved in infectious diseases, inflammatory diseases & cancer. The company has late-stage compounds in development & continues to discover additional compounds & to progress them to meet the unmet medical needs of patients and physicians.
1-Year Stock Chart:
Source: Bloomberg
